MedAll

Are you attending ASNR? Join our expert panel including Tammie Benzinger, MD, PhD — Hugh Monroe Wilson Professor of Radiology and Chief of MRI Service at Washington University School of Medicine — for a free, accredited CME session reviewing the latest clinical data and evidence-based approaches to ARIA detection and monitoring in Alzheimer's Disease. Prof. Benzinger’s work focuses on PET and MRI biomarkers for Alzheimer’s disease and related neurodegenerative disorders. 🎓 0.75 AMA PRA Category 1 Credits™ 👉 Follow the link below to pre-register — exclusively for ASNR attendees only app.medalleducation.com/event-listings… @TheASNR @tlsmit1 #ASNR #Neuroradiology #CME #AlzheimersDisease

Calling all ASNR attendees: Join our free accredited ARIA Clinical Decision Academy session on ARIA Detection, Escalation, and System Readiness, with live Q&A. Our expert panel includes Dr. Petrice M. Cogswell, Associate Professor of Radiology and Consultant in the Division of Neuroradiology at Mayo Clinic, Rochester. A leading expert in advanced neuroimaging, her research focuses on the intersection of quantitative MRI, machine learning, and biomarker modeling to enhance the diagnosis of neurodegenerative disorders. 🎓 0.75 AMA PRA Category 1 Credits™ 👇 Follow the link below to pre-register – exclusively for ASNR attendees only app.medalleducation.com/event-listings… @TheASNR hashtag#ASNR2026 hashtag#NeuroImaging hashtag#CME hashtag#Radiology

👩‍⚕️ Calling all healthcare professionals: we’d love your input. In routine NSCLC practice, how often do operational or multidisciplinary factors affect implementation of ADC care pathways?

Calling all healthcare professionals: we’d love your input. In NSCLC care, how challenging is balancing toxicity considerations with maintaining long-term ADC treatment strategies?

🥼 Calling all healthcare professionals: we’d love your input. In evolving NSCLC treatment pathways, how challenging is deciding where ADCs fit alongside immunotherapy, chemotherapy, and targeted therapies?

👋 Calling all healthcare professionals: we’d love your input. In today’s evolving NSCLC landscape, how much of a challenge is identifying which patients may be appropriate for HER2- or TROP2-directed ADC approaches?

💬 HCPs, we’d value your perspective We’re exploring evolving treatment pathways in rheumatology. Is the following a gap in clinical practice? Integrating generic JAK inhibitors into evidence-based care while maintaining individualized treatment decisions:

📊 HCPs, we’d love your perspective We’re exploring how emerging evidence is applied in practice. Is the following a gap in clinical practice? Applying emerging real-world evidence to JAK inhibitor sequencing and long-term disease management:

🩺 HCPs, we’d value your insight We’re exploring safety-based decision-making in rheumatology. Is the following a gap in clinical practice? Individualizing JAK inhibitor selection and monitoring based on evolving safety risks and patient comorbidities:

🩺HCP insights needed: Diagnostic pathway implementation Is this a gap in clinical practice? Challenges implementing biomarker-enabled Alzheimer’s diagnostic pathways in practice

👋HCP insights needed: Biomarker interpretation Is this a gap in clinical practice? Difficulty interpreting Alzheimer’s biomarker results and diagnostic implications

📊HCP insights needed: Blood-based biomarkers Is this a gap in clinical practice? Uncertainty around the role of blood-based biomarkers in Alzheimer’s diagnostic pathways

👋HCP insights needed: Fluid and imaging biomarkers Is this a gap in clinical practice? Difficulty integrating CSF and PET biomarkers into routine Alzheimer’s diagnostic workflows

🩺HCP insights needed: Early Alzheimer’s diagnosis Is this a gap in clinical practice? Limited confidence identifying early Alzheimer’s disease and patients suitable for biomarker testing

👋HCPs insights wanted We’re exploring BCMA bispecific antibodies in RRMM Is the following a gap in clinical practice? HCPs lack standardised processes to safely initiate BCMA BsAb therapy, including patient selection, baseline assessment, logistics and consent

📊HCPs insights wanted We’re exploring BCMA bispecific antibodies in RRMM Is the following a gap in clinical practice? HCPs lack confidence managing CRS, ICANS and infection prevention strategies in community settings

👋Quick question for clinicians We’re exploring individualized treatment selection in multiple myeloma Is the following a gap in clinical practice? Individualizing treatment strategies for older, frail, or medically complex patients with multiple myeloma

🩺Calling all HCPs We’re exploring toxicity monitoring and supportive care in multiple myeloma Is the following a gap in clinical practice? Proactively monitoring and managing toxicities associated with newer immunotherapy-based treatment approaches in multiple myeloma

📊HCP perspectives wanted We’re exploring how emerging clinical evidence is applied in multiple myeloma care Is the following a gap in clinical practice? Interpreting and applying emerging clinical trial data to real-world treatment decisions in multiple myeloma

📣HCPs, we want to hear from you We’re exploring treatment decision-making in RRMM Is the following a gap in clinical practice? Selecting and sequencing therapies for patients with relapsed/refractory multiple myeloma following exposure to multiple therapeutic classes.

📣 HCPs We’re exploring supportive care decision-making in cancer cachexia. Is the following a gap in clinical practice? Selecting and integrating strategies to preserve appetite, lean body mass, physical function, and treatment tolerance in patients with cancer cachexia: